Roche Holding AG Website

Roche Holding AG

SWX-ROG

Company Overview

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.

  • Name

    Roche Holding AG

  • CEO

    Dr. Thomas Schinecker

  • Website

    www.roche.com

  • Sector

    Pharmaceuticals

  • Year Founded

    1896

Profile

  • Market Cap

    CHF 215.82B

  • EV

    CHF 247.12B

  • Shares Out

    796.79M

  • Revenue

    CHF 60.58B

  • Employees

    103,605

Margins

  • Gross

    74.54%

  • EBITDA

    34.73%

  • Operating

    29.71%

  • Pre-Tax

    21.67%

  • Net

    17.53%

  • FCF

    20.44%

Returns (5Yr Avg)

  • ROA

    15.04%

  • ROTA

    58.45%

  • ROE

    38.58%

  • ROCE

    33.37%

  • ROIC

    23.59%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    CHF 301.11

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    CHF 8,814M

  • Net Debt

    CHF 27.36B

  • Debt/Equity

    1.1

  • EBIT/Interest

    17.17

Growth (CAGR)

  • Rev 3Yr

    -0.82%

  • Rev 5Yr

    -0.37%

  • Rev 10Yr

    2.2%

  • Dil EPS 3Yr

    -6.59%

  • Dil EPS 5Yr

    -0.68%

  • Dil EPS 10Yr

    0.6%

  • Rev Fwd 2Yr

    4.59%

  • EBITDA Fwd 2Yr

    7.27%

  • EPS Fwd 2Yr

    4.57%

  • EPS LT Growth Est

    6.19%

Dividends

  • Yield

    —

  • Payout

    72.14%

  • DPS

    CHF 9.6

  • DPS Growth 3Yr

    1.8%

  • DPS Growth 5Yr

    1.99%

  • DPS Growth 10Yr

    2.1%

  • DPS Growth Fwd 2Yr

    2.65%

SWX:ROG